Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment

Liver International

Volumn 31, Issue 9, 2011, Pages 1395-1405

  Grabowski, Jan ^a   Yurdaydìn, Cihan ^b   Zachou, Kalliopi ^c   Buggisch, Peter ^d   Hofmann, Wolf P ^e   Jaroszewicz, Jerzy ^a,f   Schlaphoff, Verena ^a   Manns, Michael P ^a   Cornberg, Markus ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF THESSALY   (Greece)

^d Ifi Institute for Interdisciplinary Infectiology   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cellular immune responses; Delta hepatitis; HDV; IFN treatment; Interferon alfa 2a; IP 10

Indexed keywords

ADEFOVIR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 2; PEGINTERFERON ALPHA;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOKINE RESPONSE; DELTA AGENT HEPATITIS; FEMALE; HEPATITIS DELTA VIRUS; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ADENINE; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CYTOKINES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 80052525365     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02593.x     Document Type: Article

References (33)

1. Rizzetto M, Hoyer B, Canese MG, et al. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A 1980; 77: 6124-8.
2. Taylor JM. Hepatitis delta virus. Virology 2006; 344: 71-6.
3. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85.
4. Le Gal F, Gault E, Ripault MP, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006; 12: 1447-50.
5. Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-35.
6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
7. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
8. Grabowski J, Wedemeyer H. Hepatitis delta: Immunopathogenesis and clinical challenges. Dig Dis 2010; 28: 133-8.
9. Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430-7.
10. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-52.
11. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-54.
12. Aslan N, Yurdaydin C, Wiegand J, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepatol 2006; 13: 505-14.
13. Nisini R, Paroli M, Accapezzato D, et al. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. J Virol 1997; 71: 2241-51.
14. Huang YH, Tao MH, Hu CP, Syu WJ, Wu JC. Identification of novel HLA-A*0201-restricted CD8+T-cell epitopes on hepatitis delta virus. J Gen Virol 2004; 85(Part 10): 3089-98.
15. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepatol 2010; 17: 749-56.
16. Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
17. Cramp ME, Rossol S, Chokshi S, et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
18. Gallagher KM, Lauder S, Rees IW, Gallimore AM, Godkin AJ. Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen. J Immunol 2009; 183: 2915-20.
19. Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009; 199: 819-28.
20. Pilli M, Zerbini A, Penna A, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007; 133: 1132-43.
21. Wiegand J, Cornberg M, Aslan N, et al. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. Antivir Ther 2007; 12: 303-16.
22. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004; 40: 87-97.
23. Suneetha PV, Schlaphoff V, Wang C, et al. Effect of peptide pools on effector functions of antigen-specific CD8+T cells. J Immunol Methods 2009; 342: 33-48.
24. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207-19.
25. Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-50.
26. Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-204.
27. Cornberg M, Protzer U, Dollinger MM, et al. Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-)infection: upgrade of the guideline, AWMF-register 021/011 Z. Gastroenterology 2007; 45: 525-74.
28. Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8+T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005; 79: 12979-88.
29. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
30. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-25.
31. Mohty AM, Grob JJ, Mohty M, et al. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 2010; 215: 113-23.
32. Padovan E, Spagnoli GC, Ferrantini M, Heberer M.IFN-{alpha}2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71: 669-76.
33. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol 2010; 52: 627-9.